Floatz logo

Ocrelizumab

Relapsing-Remitting Multiple Sclerosis

Biocadmonoclonal_antibodyPhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
81/ 100

Competitive context

70 Active assets in the Relapsing-Remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Natalizumab
Biogen
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Fingolimod
TG Therapeutics, Inc.
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Cladribine
Uppsala University
Phase 4BBB

View all 50 →

Same molecule, other indications

Ocrelizumab is also rated in:

primary progressive multiple sclerosisActive
BBB
Indicative · Phase 4
76 / 100
View asset →
multiple sclerosisActive
BBB
Indicative · Phase 4
72 / 100
View asset →
secondary progressive multiple sclerosisActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →